Disculpa, pero esta entrada está disponible sólo en Inglés Estadounidense. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

General, non-pharmacovigilance fees payable to EMA by applicants and marketing-authorisation holders are increasing by 1.6% on 1 April 2020.

Full details of the new fee levels are available in Commission Regulation (EU) No 2020/422 amending Council Regulation (EC) No 297/95, its implementing rules and the corresponding explanatory note on fees, published on 19 March 2020. These documents include the new fees for all types of procedures handled by the Agency, except for pharmacovigilance procedures.

Every year, the Agency adjusts its fees on 1 April, in line with the European Union (EU) inflation rate for the previous year. The current increase reflects the inflation rate for 2019, as published by Eurostat, the EU’s statistical office.

All applications received by 31 March will be charged the current fee and reduction rates. Applications received after that date will be charged the adjusted fees. For scientific advice and protocol assistance, the cut-off point will be the date of validation of the request for advice. For annual fees, the anniversary date of the decision granting the marketing authorisation defines the applicable fee and consequently a new fee will be applicable at the time of any anniversary on or after 1 April 2020.

In addition, new fees have been introduced for consultations on medical devices (human medicines) and for assessments on whether a full maximum residue limit (MRL) evaluation is required or not for a chemical-unlike biological substance (veterinary medicines).

Fees charged for pharmacovigilance procedures in accordance with Regulation (EU) 658/2014 are expected to be revised later in 2020, taking into account the 2018 and 2019 inflation rates.

Posted on the EMA website on 1 April 2020